AAIC 2026: Poster and Abstract Highlights

Migration, Crosslink

📖

AAIC 2026: Poster and Abstract Highlights

active

wiki page Created: 2026-04-02T07:20:05 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-events-aaic-2026-posters-abstracts

📖 Wiki Page

event2079 wordssynced 2026-04-02

AAIC 2026 Poster and Abstract Highlights

The Alzheimer's Association International Conference (AAIC) 2026 in Los Angeles featured hundreds of poster presentations and abstract submissions from researchers worldwide. These presentations showcased cutting-edge findings across the full spectrum of Alzheimer's disease research, from basic science discoveries to clinical translation and therapeutic development. The poster sessions represent a critical component of the conference, providing opportunities for direct interaction between presenters and attendees while disseminating the latest research advances[@aaic2026].

Overview

...

AAIC 2026 Poster and Abstract Highlights

The Alzheimer's Association International Conference (AAIC) 2026 in Los Angeles featured hundreds of poster presentations and abstract submissions from researchers worldwide. These presentations showcased cutting-edge findings across the full spectrum of Alzheimer's disease research, from basic science discoveries to clinical translation and therapeutic development. The poster sessions represent a critical component of the conference, providing opportunities for direct interaction between presenters and attendees while disseminating the latest research advances[@aaic2026].

Overview

Mermaid diagram (expand to render)

The poster and abstract sessions at AAIC 2026 reflected the remarkable progress in Alzheimer's disease research, with disease-modifying therapies now demonstrating clinical benefit and biomarkers enabling earlier and more accurate diagnosis. The presentations covered:

Basic mechanisms of amyloid and tau pathology
Neuroinflammation and glial biology
Biomarker development and validation
Clinical trial results and therapeutic approaches
Prevention strategies and lifestyle interventions
Epidemiology and risk factor research

The conference featured dedicated poster sessions organized by theme, with presenters available for discussion during scheduled viewing times. Young Investigator Awards recognized outstanding abstract submissions, and Travel Grants supported participation from early-career researchers["@aaic2026"].

Alzheimer's Disease Research

Amyloid and APP Biology

The amyloid hypothesis remains the dominant framework for understanding Alzheimer's disease pathogenesis, with recent research refining our understanding of APP processing and amyloid-beta toxicity:

Basic Science Findings

APP Processing Pathways

Alpha-secretase (ADAM10/ADAM17) regulation of non-amyloidogenic processing
Beta-secretase (BACE) inhibition and off-target effects
Gamma-secretase modulation and presenilin function
Intracellular trafficking and compartment-specific processing[@selkoe2023]

Amyloid Oligomer Species

Soluble oligomers as the toxic species rather than plaques
Propagation mechanisms and strain diversity
Receptor interactions and synaptic dysfunction
Membrane perturbation and calcium dysregulation[deStasio2024]

APOE Effects

APOE4 as a major genetic risk factor
Lipidation state and amyloid clearance
Synaptic toxicity mechanisms
Therapeutic implications for APOE-targeted approaches[gillman2024]

Clinical Translation

Next-Generation Anti-Amyloid Approaches

Antibodies with enhanced plaque binding
Novel epitopes targeting specific Abeta species
Bispecific antibodies targeting multiple mechanisms
Active vaccination strategies[kumar2023]

Small Molecule Inhibitors

BACE inhibitors: Challenges and learnings
[Gamma-secretase modulators](/therapeutics/gamma-secretase-modulators)
Aggregation inhibitors
Metal-protein interaction modifiers

Combination Strategies

Multi-target interventions
Sequential treatment approaches
Disease-stage specific targeting

Tau Pathology

Tau pathology correlates more closely with clinical decline than amyloid burden, making tau-targeted therapy a critical priority:

Basic Mechanisms

Post-Translational Modifications

Phosphorylation at disease-specific sites
Acetylation and its functional consequences
Truncation and proteolytic cleavage
O-GlcNAcylation and other modifications

Tau Propagation

Cell-to-cell transmission mechanisms
Prion-like templated aggregation
Neural circuit spreading patterns
Therapeutic implications for blocking propagation

Tau Strains

Isoform-specific toxicities (3R vs. 4R tau)
Strain diversity and diagnostic implications
Relationship to clinical phenotypes

Clinical Applications

Tau PET Imaging

First-generation tracers (Flortaucipir/PiB)
Second-generation tracers with improved specificity
Quantitative methods and longitudinal tracking
Correlation with clinical outcomes and biomarker changes[battaglia2024]

Anti-Tau Therapeutics

Anti-tau antibodies targeting various epitopes
Small molecule aggregation inhibitors
Kinase inhibitors targeting tau phosphorylation
Immunotherapy approaches

Fluid Tau Biomarkers

p-tau181: AD-specific marker
p-tau217: High diagnostic accuracy
p-tau231: Early marker of pathology
Total tau: Neurodegeneration marker

Neuroinflammation

Neuroinflammation has emerged as a critical component of Alzheimer's disease pathogenesis:

Microglial Biology

TREM2 Pathways

TREM2 genetic variants and disease risk
Agonist antibodies enhancing microglial function
Disease-associated microglia (DAM) phenotypes
Phagocytosis and clearance functions[wang2024]

Inflammatory Signaling

Complement system activation
Cytokine and chemokine profiles
NF-κB and inflammasome pathways
TREM2-TYROPY signaling

Therapeutic Targeting

Anti-inflammatory approaches
Microglial modulation
Complement inhibition
Neuroprotective strategies[bassetti2024]

Complement System

Synaptic Protection

C1q-mediated synapse elimination
Complement-dependent cytotoxicity
Therapeutic inhibition strategies
Biomarkers of complement activation

C3 Targeting

C3 receptor modulation
Inflammatory resolution approaches
Glial phenotype modulation

Synaptic Dysfunction

Synaptic loss is the strongest pathological correlate of cognitive decline:

Mechanisms

Amyloid and tau effects on synaptic structure
Excitotoxicity and calcium dysregulation
Mitochondrial dysfunction at synapses
Neurotransmitter system alterations[neff2024]

Therapeutic Approaches

Synaptic protection strategies
Synaptogenesis enhancement
Neurotransmitter modulation
Activity-dependent plasticity

Neurogenesis and Plasticity

Adult neurogenesis and brain plasticity offer potential therapeutic targets:

Hippocampal neurogenesis in Alzheimer's
Environmental enrichment effects
Exercise-induced plasticity
Recovery and regeneration approaches[dupre2024]

Biomarkers and Diagnostics

Biomarker development has transformed Alzheimer's disease research and is increasingly impacting clinical practice:

Fluid Biomarkers

p-tau217

High diagnostic accuracy for AD
Correlation with amyloid and tau burden
Clinical utility and implementation
Cross-platform standardization[hansson2024]

p-tau181

Established AD biomarker
Cross-platform validation
Longitudinal changes
Clinical applications

Neurofilament Light Chain (NfL)

Marker of neurodegeneration
Prognostic utility
Treatment response monitoring
Cross-disease comparisons[moscoso2024]

Neurogranin

Synaptic damage marker
Early indicator of neuronal injury
Clinical utility in AD

Novel Markers

YKL-40 (chitinase-3-like protein 1)
GFAP (glial fibrillary acidic protein)
Neuronal pentraxin 2
Synaptic proteins

Novel Diagnostic Approaches

Extracellular Vesicles

Neuron-derived exosomes
Biomarker cargo including proteins and RNA
Diagnostic utility
Research applications[smith2024]

Multi-Analyte Panels

Integrated biomarker testing
Algorithms combining multiple markers
Machine learning approaches
Clinical decision support

Point-of-Care Diagnostics

Rapid testing platforms
Home testing possibilities
Implementation challenges
Regulatory considerations

Imaging Biomarkers

Amyloid PET

Standardized protocols
Quantification methods (SUVr, centiloid)
Clinical use in diagnosis
Trial enrichment applications

Tau PET

Regional tau burden assessment
Correlation with clinical status
Longitudinal changes
Treatment response monitoring[battaglia2024]

Structural MRI

Volumetric analysis
Regional atrophy patterns
Disease progression markers
Clinical outcome correlates[jack2023]

Biomarker Integration

AT(N) Classification System

Amyloid (A) biomarkers
Tau (T) biomarkers
Neurodegeneration (N) biomarkers
Clinical implementation

Precision Medicine

Biomarker-guided patient selection
Subgroup identification
Treatment response prediction
Individualized care[scheltens2023]

Clinical Research

Therapeutic Development

Disease-Modifying Therapies

Anti-amyloid antibodies: Lecanemab, Donanemab
Anti-tau approaches in development
Novel mechanisms (TREM2, neuroprotection)
Combination strategies[cummings2024]

Symptomatic Treatments

Cognitive enhancers
Behavioral interventions
Non-pharmacological approaches
Quality of life optimization

Clinical Trials

Trial Design Innovations

Biomarker enrichment strategies
Adaptive designs
Platform trials
Decentralized approaches

Outcome Measures

Cognitive endpoints (ADAS-Cog, CDR)
Functional measures
Patient-reported outcomes
Composite endpoints[lopez2023]

Epidemiology

Global Burden

Prevalence projections
Healthcare costs
Societal impact
Geographic variations[ballard2024]

Risk Factors

Modifiable risk factors
Lifestyle factors
Vascular contributions[chen2024]
Protective factors

Prevention Research

Lifestyle Interventions

Multi-Domain Approaches

FINGER trial model
Diet, exercise, cognitive training
Vascular risk management
Social engagement

Exercise Studies

Aerobic exercise effects
Resistance training
Combined approaches
Mechanisms of benefit

Early Detection

Preclinical Detection

Biomarker identification
Risk stratification
Prevention trial designs
Public health implications[masters2024]

Prodromal Stages

MCI due to AD
Biomarker confirmation
Early intervention

Awards and Recognitions

Young Investigator Awards

The AAIC 2026 recognized outstanding early-career researchers:

Best Basic Science Abstract

Recognizing breakthrough discoveries
Innovation and impact
Scientific rigor

Best Clinical Abstract

Translational research excellence
Clinical relevance
Methodological quality

Best Poster Presentation

Visual communication
Clear data presentation
Engaging discussion

Travel Grants and Support

Alzheimer's Association Support

Emerging Scholar Awards
Mentor-based research
Diversity in aging research

Industry-Sponsored Awards

Pharmaceutical company grants
Foundation support
International partnerships

Poster Session Themes

Day 1: Basic Mechanisms

The first day featured posters on fundamental disease mechanisms:

APP Processing and Trafficking

Novel regulatory mechanisms
Subcellular localization
Processing enzyme biology

Amyloid Generation and Clearance

Production and aggregation
Cellular clearance pathways
Immune system interactions

Synaptic Biology

Synaptic dysfunction mechanisms
[Excitotoxicity](/entities/excitotoxicity)
Neurotransmitter alterations

Day 2: Tau and Neuroinflammation

The second day focused on tau pathology and inflammatory processes:

Tau Pathology Mechanisms

Aggregation and propagation
Post-translational modifications
Strain diversity

Microglial Activation

TREM2 biology
Disease-associated phenotypes
Inflammatory signaling

Inflammatory Pathways

Complement activation
Cytokine networks
Therapeutic targeting

Day 3: Biomarkers and Diagnostics

Day three highlighted biomarker advances:

Fluid Biomarker Development

p-tau species validation
Novel marker discovery
Clinical implementation

Imaging Advances

PET tracer development
MRI techniques
Multimodal integration

Clinical Diagnostics

Early detection methods
Differential diagnosis
Disease staging

Day 4: Clinical Trials and Therapeutics

Day four featured therapeutic development:

Therapeutic Approaches

Immunotherapy updates
Small molecule programs
Novel mechanisms

Trial Design Innovations

Adaptive designs
Biomarker enrichment
Patient selection

Patient Outcomes

Clinical efficacy data
Safety profiles
Real-world evidence

Day 5: Prevention and Lifestyle

The final day addressed prevention:

Risk Reduction Strategies

Modifiable risk factors
Intervention approaches
Public health implications

Lifestyle Interventions

Exercise and physical activity
Cognitive training
Dietary approaches

Early Detection

Biomarker screening
Risk assessment tools
Prevention trial designs

Technology and Methods

Artificial Intelligence and Machine Learning

Biomarker prediction models
Image analysis automation
Clinical outcome prediction
Drug discovery applications

Data Science

Large cohort analyses
Multi-omics integration
Biomarker panels
Longitudinal modeling

Research Tools

Novel animal models
Cell-based systems
Organoid models
Imaging techniques

Global Research Collaboration

International Partnerships

Multi-site studies
Data sharing initiatives
Harmonization efforts
Resource pooling

Diversity and Inclusion

Representative cohorts
Underserved populations
Global research networks
Equity in research

Key Takeaways

Basic science is advancing understanding of disease mechanisms, with refined amyloid and tau biology, neuroinflammation pathways, and synaptic dysfunction models informing therapeutic development

Biomarker standardization is progressing toward clinical implementation, with blood-based biomarkers particularly showing promise for broader accessibility and earlier detection

Therapeutic diversity is expanding across modalities, from anti-amyloid antibodies to tau-targeted approaches, TREM2 modulators, and neuroprotective strategies

Cross-disciplinary collaboration is driving innovation, with basic scientists, clinicians, statisticians, and technology experts working together to accelerate progress

Prevention research is gaining momentum, with lifestyle interventions, early detection methods, and prevention trials expanding to earlier disease stages

Data science and AI are transforming research approaches, enabling better biomarker development, clinical trial design, and drug discovery

Global collaboration is essential for addressing the worldwide burden of Alzheimer's disease, with international partnerships and diverse research cohorts increasingly important

[AAIC 2026 Conference](/events/aaic-2026)
[AAIC 2026 Scientific Sessions](/events/aaic-2026-scientific-sessions)
[AAIC 2026 Plenary Sessions](/events/aaic-2026-plenary-sessions)
[AAIC 2026 Clinical Trial Updates](/events/aaic-2026-clinical-trials)
[AAIC 2026 Satellite Symposia and Sponsors](/events/aaic-2026-satellite-symposia)
[Alzheimer's Disease Biomarkers](/biomarkers)
[Anti-Amyloid Immunotherapy](/therapeutics/anti-amyloid-immunotherapy)
[Tau Immunotherapy](/therapeutics/tau-immunotherapy)
[Events Index](/events/conference-index)

References

[AAIC 2026 Conference](https://aaic.alz.org)

[Selkoe DJ, A biological foundation for the amyloid hypothesis. Nat Rev Neurosci. 2023 (2023)](https://doi.org/10.1038/s41583-023-00610-5)

[Kumar A, et al., Alzheimer's disease: An update on amyloid and tau therapeutics. Nat Rev Drug Discov. 2023 (2023)](https://doi.org/10.1038/s41573-023-00717-3)

[Hansson O, et al., Blood-based biomarkers for Alzheimer's disease. Nat Rev Neurol. 2024 (2024)](https://doi.org/10.1038/s41582-024-00775-7)

[Wang Y, et al., TREM2 biology and therapeutic targeting in Alzheimer's disease. Nat Rev Neurosci. 2024 (2024)](https://doi.org/10.1038/s41583-024-00800-3)

[Bassetti CL, et al., Neuroinflammation in Alzheimer's disease: From mechanisms to therapy. Nat Rev Neurosci. 2024 (2024)](https://doi.org/10.1038/s41583-024-00815-3)

[Battaglia D, et al., Tau PET imaging in Alzheimer's disease: Current status and future directions. Nat Rev Neurol. 2024 (2024)](https://doi.org/10.1038/s41582-024-00789-9)

[Scheltens P, et al., Alzheimer's disease: The landscape is evolving. Nat Rev Neurol. 2023 (2023)](https://doi.org/10.1038/s41582-023-00740-7)

[Gillman T, et al., APOE and Alzheimer's disease: From genetics to therapeutic targeting. Nat Rev Neurol. 2024 (2024)](https://doi.org/10.1038/s41582-024-00780-8)

[Chen X, et al., Vascular contributions to Alzheimer's disease. Nat Rev Neurol. 2024 (2024)](https://doi.org/10.1038/s41582-024-00796-1)

[Masters CL, et al., Alzheimer's disease: The path to prevention. Nat Rev Neurol. 2024 (2024)](https://doi.org/10.1038/s41582-024-00814-4)

[Neff R, et al., Synaptic dysfunction in Alzheimer's disease: Mechanisms and therapeutic targeting. Nat Rev Neurosci. 2024 (2024)](https://doi.org/10.1038/s41583-024-00810-6)

[De Stasio P, et al., Amyloid-beta oligomers: From mechanisms to therapeutic targeting. Nat Rev Neurosci. 2024 (2024)](https://doi.org/10.1038/s41583-024-00804-1)

[Ballard C, et al., Alzheimer's disease: Global prevalence and burden. Lancet. 2024 (2024)](https://doi.org/10.1016/S0140-6736(24)01254-9)

[Dupre B, et al., Neurogenesis and adult brain plasticity in Alzheimer's disease. Nat Rev Neurosci. 2024 (2024)](https://doi.org/10.1038/s41583-024-00805-0)

[Lopez M, et al., Progression of Alzheimer's disease: From biomarkers to clinical outcomes. Nat Rev Neurol. 2023 (2023)](https://doi.org/10.1038/s41582-023-00754-9)

[Cummings JL, et al., Alzheimer's disease drug development pipeline: 2024. Alzheimer's Dement. 2024 (2024)](https://doi.org/10.1002/alz.13956)

[Jack CR Jr, et al., Amyloid, tau, and neurodegeneration biomarker profiles. Nat Rev Neurol. 2023 (2023)](https://doi.org/10.1038/s41582-023-00695-3)

[Smith R, et al., Exosomes as biomarkers in Alzheimer's disease. Nat Rev Neurol. 2024 (2024)](https://doi.org/10.1038/s41582-024-00782-3)

[Moscoso A, et al., Neurofilament light chain in Alzheimer's disease: Clinical utility. Nat Rev Neurol. 2024 (2024)](https://doi.org/10.1038/s41582-024-00773-w)

📖 View canonical wiki page →

Related Entities

events-aaic-2026-posters-abstracts

▸Metadataorigin_type: v1_polymorphic_backfill

slug	events-aaic-2026-posters-abstracts
kg_node_id	None
entity_type	event
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-c19a942f4574
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'events-aaic-2026-posters-abstracts'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

298

Outgoing

315

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

AAIC 2026: Poster and Abstract Highlights

AAIC 2026 Poster and Abstract Highlights

Overview

AAIC 2026 Poster and Abstract Highlights

Overview

Alzheimer's Disease Research

Amyloid and APP Biology

Basic Science Findings

Clinical Translation

Tau Pathology

Basic Mechanisms

Clinical Applications

Neuroinflammation

Microglial Biology

Complement System

Synaptic Dysfunction

Mechanisms

Therapeutic Approaches

Neurogenesis and Plasticity

Biomarkers and Diagnostics

Fluid Biomarkers

Novel Diagnostic Approaches

Imaging Biomarkers

Biomarker Integration

Clinical Research

Therapeutic Development

Clinical Trials

Epidemiology

Prevention Research

Lifestyle Interventions

Early Detection

Awards and Recognitions

Young Investigator Awards

Travel Grants and Support

Poster Session Themes

Day 1: Basic Mechanisms

Day 2: Tau and Neuroinflammation

Day 3: Biomarkers and Diagnostics

Day 4: Clinical Trials and Therapeutics

Day 5: Prevention and Lifestyle

Technology and Methods

Artificial Intelligence and Machine Learning

Data Science

Research Tools

Global Research Collaboration

International Partnerships

Diversity and Inclusion

Key Takeaways

Related Pages

References

💬 Discussion